Showing posts with label Equine. Show all posts
Showing posts with label Equine. Show all posts

Thursday, February 25, 2016

Equine Erythropoietin (EPO) Do-It-Yourself ELISA, ≤10 Plates

The Equine Erythropoietin Do-It-Yourself ELISA contains capture antibody, protein standard, and detection antibody for development of a Equine EPO ELISA. The antibodies have been determined to function in an ELISA with the standard provided. Optimal buffers, concentrations, incubation times, incubation temperatures, and methods for the ELISA have not been determined.

Erythropoietin (EPO) is an essential hormone for red blood cell production. Without it, definitive erythropoiesis does not take place. Erythropoietin has its primary effect on red blood cell progenitors and precursors by promoting their survival through protecting these cells from apoptosis. It is the primary erythropoietic factor that cooperates with various other growth factors (e.g., IL-3, IL-6, glucocorticoids, and SCF) involved in the development of erythroid lineage from multipotent progenitors. Erythropoietin has a range of actions including vasoconstriction-dependent hypertension, stimulating angiogenesis, and inducing proliferation of smooth muscle fibers.


Friday, February 19, 2016

VEGF-A Across Species

Kingfisher Biotech's portfolio of VEGF-A recombinant proteins includes,  bovine,  canine, equine,  feline,  mouse,  ovine,  rabbit , rat,  swine, and zebrafish VEGF-A.

Vascular endothelial growth factor (VEGF) proteins stimulate vasculogenesis and angiogenesis. They are part of the system that restores the oxygen supply to tissues when blood circulation is inadequate. The normal function of VEGF proteins is to create new blood vessels during embryonic development, new blood vessels after injury, muscle following exercise, and new vessels (collateral circulation) to bypass blocked vessels. The VEGF family has six members, including VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and Placental Growth Factor (PGF). Activity of VEGF-A, as its name implies, has been studied mostly on cells of the vascular endothelium, although it does have effects on a number of other cell types (e.g., stimulation monocyte/macrophage migration, neurons, cancer cells, kidney epithelial cells). In vitro, VEGF-A has been shown to stimulate endothelial cell mitogenesis and cell migration. VEGF-A is also a vasodilator and increases microvascular permeability and was originally referred to as vascular permeability factor (VPF).

A recent bioassay of our bovine, canine, and mouse VEGF-A based on the proliferation of HUVECs demonstrated that all three proteins are highly active on the human cell line.



Wednesday, July 8, 2015

New Products - July 2015

Kingfisher Biotech, Inc. is committed to accelerating basic veterinary research and human disease research done in animal models by developing and commercializing research reagents specific for a variety of species, including bovine, canine, caprine, chicken, dolphin, equine, feline, guinea pig, hamster, human, mouse, ovine, rabbit, rat, swine, and turkey. We have just started adding cynomolgus monkey and zebrafish products. Currently, we offer over 1200 recombinant proteins, polyclonal antibodies, monoclonal antibodies and ELISA kits for animal health and animal model research. Our products are primarily cytokines, chemokines, interferons, and growth factors. Our product development queue is filled mainly by customer requests. If there is a product that you are looking for and can't find, please send us an email.

Below is a list of our newest recombinant proteins with links to website with additional information on each product.

Wednesday, June 17, 2015

EPO and Erythropoiesis


The orchestration of a complex, hierarchical process like erythropoiesis requires the precise coordination of a host of cellular factors that work either in concert or at distinct stages of the process, to regulate effective and sufficient formation of RBCs. The principal regulator of erythropoiesis is Erythropoietin (EPO), a heavily glycosylated protein belonging to the class I cytokine family (Jelkmann, 2004). EPO exerts its effects on erythropoiesis by binding to and activating the EPOreceptor (EpoR), a high affinity receptor that is predominantly expressed on the surface of immature erythroid cells. EpoR belongs to the type I cytokine receptor family and exists as a homodimer. Upon ligand binding, EpoR, which lacks intrinsic catalytic activity, undergoes a conformational change and associates with Janus Kinase 2 (JAK2). JAK2 phosphorylates the ligand-activated EpoR, generating multiple docking sites for signaling molecules, and leading to activation of several signal transduction pathways (Watowich, 2011). While one of the earliest studied signaling pathways activated through the EPO-EpoR cascade is the Janus Kinase and Signal Transducer and Activator of Transcription (JAK/STAT) pathway, phosphorylated EpoR induces activation of other cellular signaling cascades including the mitogen-activated protein kinase/extracellular signal-related kinase (MAPK/ERK) and the phosphatidylinositol 3-kinase /protein kinase B (PI-3K/AKT) pathways (Ingley et al., 2004). These pathways impact erythropoiesis by temporally regulating transcription of genes involved in survival, differentiation, and cell proliferation depending on the stage of erythroid maturation. For example, survival signals are provided to CFU-E cells, the most EPO-sensitive cells amongst the erythroid progenitors, as well as to erythroblasts. The importance of EPO-EpoR signaling in erythropoiesis has been demonstrated by EPO-null and EpoR-null mouse models, which are both embryonically lethal, owing to a lack of erythropoiesis in the fetus (Wu et al., 1995). While the EPO-EpoR signaling axis serves as the central hub for erythropoiesis regulation, several other molecular signals, both extrinsic and intrinsic, are involved and serve to further fine-tune the progression of the multi-faceted process of erythropoiesis (Ingley, 2012; Ingley et al., 2004; Kuhrt and Wojchowski, 2015). more... 

Check out Kingfisher Biotech's growing portfolio of EPO products, including recombinant proteins, polyclonal antibodies and ELISA Kits.

Thursday, May 28, 2015

New Products - May 2015

Kingfisher Biotech, Inc. is committed to accelerating basic veterinary research and human disease research done in animal models by developing and commercializing research reagents specific for a variety of species, including bovine, canine, caprine, chicken, dolphin, equine, feline, guinea pig, hamster, human, mouse, ovine, rabbit, rat, swine, and turkey. We have just started adding cynomolgus monkey and zebrafish products. Currently, we offer over 1200 recombinant proteins, polyclonal antibodies, monoclonal antibodies and ELISA kits for animal health and animal model research. Our products are primarily cytokines, chemokines, interferons, and growth factors. Our product development queue is filled mainly by customer requests. If there is a product that you are looking for and can't find, please send us an email.

Below is a list of our newest recombinant proteins and specialty products with links to website with additional information on each product.

Thursday, April 16, 2015

New Recombinant Proteins - April 2015

Kingfisher Biotech, Inc. is committed to accelerating basic veterinary research and human disease research done in animal models by developing and commercializing research reagents specific for a variety of species, including bovine, canine, caprine, chicken, dolphin, equine, feline, guinea pig, hamster, human, mouse, ovine, rabbit, rat, swine, and turkey. We will continue to add species as our customer request specific reagents for their research. Currently, we offer over 1200 recombinant proteins, polyclonal antibodies, monoclonal antibodies and ELISA kits for animal health and animal model research. Our products are primarily cytokines, chemokines, interferons, and growth factors. Our product development queue is filled mainly by customer requests. If there is a product that you are looking for and can't find, please send us an email.

Below is a list of our newest proteins with links to website with additional information on each protein.

Thursday, April 9, 2015

IFN gamma Recombinant Proteins - Bovine, Canine, Chicken, Dolphin, Equine, Feline, Human, Mouse, Ovine, Rabbit, and Swine

Bovine, Canine, Chicken, Dolphin, Equine, Feline, Human, Mouse, Ovine, Rabbit, and Swine IFN gamma Recombinant Proteins

IFN-gamma, or type II interferon, is a cytokine that is critical for innate and adaptive immunity against viral and intracellular bacterial infections and for tumor control. Aberrant IFN-gamma expression is associated with a number of autoinflammatory and autoimmune diseases. The importance of IFN-gamma in the immune system stems in part from its ability to inhibit viral replication directly, but, most important, derives from its immunostimulatory and immunomodulatory effects. IFN-gamma is produced predominantly by natural killer (NK) and natural killer T (NKT) cells as part of the innate immune response, and by CD4 and CD8 cytotoxic T lymphocyte (CTL) effector T cells once antigen-specific immunity develops.

Kingfisher Biotech offers bovine, canine, chicken, dolphin, equine, feline, human, mouse, ovine, rabbit, and swine IFN gamma recombinant proteins. Our proteins are produced in yeast, making them naturally endotoxin-free - perfect for cell culture applications. 

IFN gamma Homology Across Species



Thursday, March 12, 2015

Equine IFNβ1 Do-It-Yourself ELISA

Type I interferons comprise a vast and growing group of IFN proteins. Homologous molecules to type I IFNs are found in many species, including all mammals, and some have been identified in birds, reptiles, amphibians and fish species. The mammalian types are designated IFN-α, IFN-β, IFN-κ, IFN-δ, IFN-ε, IFN-τ, IFN-ω, and IFN-ζ (also known as limitin). They are mainly involved in innate immune response against viral infection.

The Equine IFNβ1 Do-It-Yourself ELISA contains capture antibody, standard, and detection antibody for development of a Equine IFNβ1 ELISA. The antibodies have been determined to function in an ELISA with the standard provided. Optimal buffers, concentrations, incubation times, incubation temperatures, and methods for the ELISA have not been determined. A working knowledge of ELISA is strongly recommended. The quantities of components provided are not matched. Components may also be purchased separately. 

ComponentUsageQuantityCatalog #
Anti-Equine IFNβ1 PAbCapture Antibody100 µgKPB1001E-100
Biotinylated Anti-Equine IFNβ1 PAb Detection Antibody50 µgKPB1002E-050
Equine IFNβ1 ProteinStandard5 µgRP935E-005
The Equine IFNβ1 Do-It-Yourself ELISA is intended for use in animal model and animal health research.

Thursday, February 19, 2015

Canine, Equine, and Swine Erythropoietin Recombinant Proteins

Erythropoietin (EPO) is an essential hormone for red blood cell production. Without it, definitive erythropoiesis does not take place. Erythropoietin has its primary effect on red blood cell progenitors and precursors by promoting their survival through protecting these cells from apoptosis. It is the primary erythropoietic factor that cooperates with various other growth factors (e.g., IL-3, IL-6, glucocorticoids, and SCF) involved in the development of erythroid lineage from multipotent progenitors. Erythropoietin has a range of actions including vasoconstriction-dependent hypertension, stimulating angiogenesis, and inducing proliferation of smooth muscle fibers. It can increase iron absorption by suppressing the hormone hepcidin. EPO is highly glycosylated, with half-life in blood around five hours. The half-life of EPO may vary between endogenous and various recombinant versions. Additional glycosylation or other alterations of EPO via recombinant technology have led to increased stability in blood. EPO binds to the erythropoietin receptor on the red cell progenitor surface and activates a JAK2 signaling cascade. Erythropoietin receptor expression is found in a number of tissues, such as bone marrow and peripheral/central nervous tissue. In the bloodstream, red cells themselves do not express erythropoietin receptor, so cannot respond to EPO. However, indirect dependence of red cell longevity in the blood on plasma erythropoietin levels has been reported, a process termed neocytolysis. Kigfisher Biotech's recombinant Erythropoietin proteins are intended for use in animal model and animal health research and can be used in cell culture, as an EPO ELISA Standard, and as a Western Blot Control. Canine, equine, and swine EPO recombinant proteins are now available from Kingfisher Biotech.

Kingfisher Biotech, Inc. is committed to accelerating basic veterinary research and human disease research done in animal models by developing and commercializing research reagents specific for a variety of species, including bovine, canine, caprine, chicken, dolphin, equine, feline, guinea pig, hamster, human, mouse, ovine, rabbit, rat, swine, and turkey. We will continue to add species as our customer request specific reagents for their research. Currently, we offer over 1200 recombinant proteins, polyclonal antibodies, monoclonal antibodies and ELISA kits for animal health and animal model research. Our products are primarily cytokines, chemokines, interferons, and growth factors. Our product development queue is filled mainly by customer requests. If there is a product that you are looking for and can't find, please send us an email.

Thursday, February 12, 2015

sCD40 Ligand - Canine, Chicken, Equine, & Swine Recombinant Proteins

CD40 Ligand (CD40LG) is a transmembrane protein that is a member of the TNF superfamily. In addition to existing in a membrane bound form, CD40LG can also be released as a soluble molecule (sCD40LG), which has been shown to have biological functions.

CD40 interacts with CD40 ligand (aka CD40LG, TNFSF5 or CD154), which is predominantly expressed on activated CD4+ T-cells. CD40LG is transiently expressed on activated T-cells and plays a crucial role in B-cell function. Activated T-cells expressing CD40LG can also interact with CD40 on endothelial cells to induce production of inflammatory cytokines. The transient expression of CD40LG allows T-cells to stimulate selected CD40-bearing cells to participate in the immune response. Increased levels of sCD40LG have been measured in patients with SLE, RA, inflammatory bowel diseases, systemic sclerosis, and Sjogren's syndrome. In culture, canine sCD40LG was shown to promote the maturation and activation of canine monocyte derived Dendritic cells. Kingfisher Biotech now offers canine, chicken, equine, and swine sCD40 Ligand recombinant proteins. The soluble CD40LG recombinant proteins can be used in cell culture, as an CD40LG ELISA Standard, and as a Western Blot Control and are intended for use in animal model and animal health research.

Saturday, March 16, 2013

Equine TNF alpha Bioactivity


Kingfisher Biotech's Equine TNFα (cat # RP0137E) was determined to be biological active by an independent laboratory in Spain. The principle of the assay is that Equine TNFα should stimulate an increase in production of IL-6 and iNOS in horse adult mesenchymal cells in culture. The Equine TNFα protein was reconstituted in 1 ml of PBS + 0.1% BSA (bovine serum albumin). The horse adult mesenchymal cells were cultured in 48 well plates, in the presence of TNFα (diluted 1:100) at a final concentration of 25 ng/ml. The cultures were maintained for 12 hours at 37 degrees C. RT-PCR and quantitative PCR (real time PCR) were used to analyze in the supernants of the cultures for IL-6 and the iNOS production. Compared to control cells, the cells stimulated with Equine TNFα had significantly higher levels of IL-6 and iNOS, showing that the Equine TNFα is biologically active.

Tuesday, July 31, 2012

Equine VEGF-A ELISA

You can now measure Equine VEGF-A. Kingfisher Biotech launched an ELISA validated for the measurement of Equine VEGF-A in cell culture supernatants. The kit contains two pre-coated plates, standard, detection antibody and streptavidin-HRP. If your research requires measurement in serum or plasma, the specialists at Kingfisher Biotech will pass on helpful tips.

Wednesday, May 2, 2012

Measurement of Equine IL-17A

PBMCs were harvested by ficoll density gradient from day old whole blood collected from an apparently healthy horse. The PBMCs were suspended at 2 x 1,000,000 cells/ml in RPMI medium containing 10% serum. PBMCs were stimulated with phytohemagglutinin (PHA; 10 µg/ml), staphylococcal enterotoxin B (SEB; 5 µg/ml) or phorbol 12-myristate 13-acetate (PMA; 10 ng/ml) and inomycin (500 ng/ml). Cell-free supernatants were harvested following three days stimulation and run in the Equine IL-17A VetSet (cat# VS0364E-002). The levels of Equine IL-17A detected are as follows:

Stimulant: Recombinant Equine IL-17A
Unstimulated: <78 pg/mL
PHA: 103 pg/mL
SEB: <78 pg/mL
PMA/Ionomycin: 283 pg/mL

Monday, November 14, 2011

TNF alpha Homology Across Species

TNF alpha is involved in systemic inflammation and is a member of a group of cytokines that stimulate the acute phase reaction. It is produced mainly by activated macrophages.

TNF alpha is able to induce fever, apoptotic cell death, sepsis (through IL-1 & IL-6 production), cachexia, and inflammation, as well as to inhibit tumorigenesis and viral replication. Because of the broad role of TNF alpha, dysregulation has been implicated in a variety of diseases.


Sunday, October 30, 2011

Rabbit as an Animal Model for Osteoarthritis Research

In humans, osteoarthritis (OA) develops either idiopathically and progresses slowly with age or secondarily to trauma and progresses rapidly. OA is associated with changes to all joint tissues including articular cartilage, subchondral bone, synovium, ligaments, and muscles. Clinically, OA-mediated joint damage results in reduced mobility, pain, and fatigue. While several disease modifying OA drugs are in various stages of development, none have yet been approved for human use. Concurrent research in humans as well as experimental animal models will be important for the discovery of new therapeutics. Since no single experimental model provides the complete picture of OA in humans, a variety of animals have served to advance OA research including mouse, rat, guinea pig, rabbit, dog, and horse. [1,2]
A broad range of rabbit OA models have been used extensively and continue to offer specific advantages over other models for OA research. The gross anatomy of the rabbit knee is very similar to that of humans. Moreover, the rabbit knee joint is large enough to enable the harvest of adequate volumes of tissue for histopathological analysis, a major limitation of smaller animal models. In adult humans, the growth plates in the long bones no longer retain the capacity for growth and are termed “closed.” This is also the case in skeletally-mature rabbits. By contrast, mouse and rat growth plates do not normally close completely and longitudinal bone growth can be reinitiated even in mature animals. This is a complicating issue for data interpretation and limits the translatability of research performed using mice and rats. [2]
Most often, skeletally-mature, male, NZW rabbits are used for OA studies in an attempt to ensure bone growth plate closure, reduce hormone fluctuation, and control for potential inter-strain variability. OA does not occur spontaneously in rabbits, but can be induced via surgical intervention (i.e., meniscectomy or anterior cruciate ligament transection [ACLT]), mechanical manipulation (i.e., impact or immobilization), or chemical application (i.e., IL-1β, collagenase, etc.). The majority of rabbit OA studies employ the ACLT model as it offers several advantages. ACLT-modified rabbits very quickly develop a wide variety of cartilage lesions post-surgically, which closely approximate many aspects of human OA. The histopathology of the rabbit ACLT model has been studied extensively and a standardized nomenclature and scoring scheme for evaluating and comparing alterations in joint structures, including changes in cartilage, synovium and bone, have been proposed. Further, a sizeable body of data derived from this model has already been amassed describing OA pathogenesis including imaging studies and effects of various potential pharmacological applications. [2]
References
1. Poole, R. et al. (2010) Recommendations for the use of preclinical models in the study and treatment of osteoarthritis. Osteoarthritis Cartilage 18(Suppl. 3):S10-S16.
2. Laverty, S. et al. (2010) The OARSI histopathology initiative – recommendations for histological assessments of osteoarthritis in the rabbit. Osteoarthritis Cartilage 18(Suppl. 3):S53-S65.